Published: 28-05-2024 11:02 | Updated: 28-05-2024 11:13

Potential future target for treating primary headache disorders

Photo: iStock Photo: iStock

Researchers at Karolinska Institutet have identified an interesting potential future therapeutic target in primary headache disorders. They have found increased amounts of a gene associated with cluster headache, MERTK, and its ligand Gal-3, in tissue from cluster headache patients. The study was recently published in The Journal of Headache and Pain.

Portrait of Caroline Ran taken outside a sunny day.

Caroline Ran. Photo: Katrin Wellfelt

“We have made the first characterization of one of the genes most strongly associated with cluster headache in GWAS, the receptor MERTK, using our biobank consisting of biological tissue from cluster headache patients and controls, as well as clinical data”, says Caroline Ran, research specialist at the same department, and shared first author of the study.

The researchers were able to show increased levels of MERTK and a ligand that binds to MERTK, Gal-3, in blood samples from cluster headache patients compared to controls.

Felicia Jennysdotter Olofsgård. Photo: Johannes Frandsén

“The trigeminal ganglion is involved in pain signaling in headache attacks and we have also been able to localize both MERTK and Gal-3 in this area in rat tissue,” says Felicia Jennysdotter Olofsgård, PhD student in Andrea Carmine Belin’s research group and co-author of the study.

A potential cure

These results are important since cluster headache is a severe primary headache disorder where the effectiveness of available treatment is insufficient and produces many side effects. Additionally, there is no cure. No drug has been developed specifically for cluster headache, despite one in one thousand being affected.

“Recently, we and research groups within the International Consortium for Cluster Headache Genetics network have identified a few key regions in our genome strongly linked to an increased risk of developing cluster headaches using GWAS. Genes in these regions could potentially represent future drug targets and we have begun to characterize one of the top candidates, MERTK, in patient and control tissue,” says Andrea Carmine Belin.

For the human studies, biological tissue from patients with a validated cluster headache diagnosis and neurologically healthy controls were collected.

As the researchers currently did not have access to human nervous tissue, they used rat tissue for studies of the trigeminal ganglion. For the animal studies, the rat trigeminal ganglion was dissected, and they studied MERKT, its ligands as well as receptors and ligands that are well known to be active in this tissue using immunohistochemistry.
Jacob Edvinsson and Lars Edvinsson, both at Lund University, took part in the study.

The next step

Primarily, the team plans to characterize MERTK and its ligands in other cell and tissue types from patients and controls and study how the activity is affected by immunological reactions in the trigeminal ganglion, as MERTK has an important role in neuroinflammation.

“We also want to examine MERTK in tissue from patients with headache diagnoses other than cluster headache to find out whether MERTK is affected specifically in cluster headache or is generally involved in other primary headaches such as migraine”, says Andrea Carmine Belin.

Cluster headache and migraines have some similar characteristics in terms of symptoms and are to some extent treated with the same type of medication.

The study was funded by the Mellby Gård Foundation and the Swedish Brain Foundation.